The following posters have been published using the OBRI research platform from 2018 to present. Note that the OBRI was originally named the Ontario Biologics Research Initiative and was later renamed to the Ontario Best Practices Research Initiative to reflect an expanded research scope:

Time to Discontinuation of Tofacitinib and TNF inhibitors in Rheumatoid Arthritis Patients with and without Methotrexate: Data from A Rheumatoid Arthritis Cohort

Rheumatologist Survey on Medical Cannabis:  Results from the Ontario Best Practices Research Initiative (OBRI)

A Comparison Between Time to Disease Activity Remission and Improvement in Patient Reported Outcomes in Rheumatoid Arthritis Patients: Results From The Ontario Best Practices Research Initiative (OBRI)

Differences Between Early and Established Rheumatoid Arthritis in Time to Achieving CDAI but Not Fatigue Low Disease Activity and Remission: Data from the OBRI Registry

Comparison between Patients with Spondyloarthritis Managed in Community Based Care Settings to those Managed in Tertiary Research Setting in Ontario: An OBRI-SPARCC Study

Factors Affecting the Discrepancy Between Patient and Physician Global Assessment of Disease Activity in Patients with Early RA: Data from the OBRI

Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the OBRI

Development of an Algorithm for the Classification of Cardiovascular Comorbidities in a large Rheumatoid Arthritis Registry: Data from the OBRI

A Descriptive Analysis of Longitudinal Changes in Relative Market Share Proportions of Biologic and DMARDs For Treatment of RA: Data From the OBRI

ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis Cohort

Collection of Anti-Rheumatic Medication From Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort

Impact of Residential Area on the Profile of Rheumatoid Arthritis Patients Initiating Their First Biologic DMARD: Results From The Ontario Best Practices Research Initiative (OBRI)

Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis Patients: Results From The Ontario Best Practices Research Initiative (OBRI)